Literature DB >> 24457342

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

Frederik N Engsig1, Robert Zangerle, Olga Katsarou, Francois Dabis, Peter Reiss, John Gill, Kholoud Porter, Caroline Sabin, Andrew Riordan, Gerd Fätkenheuer, Félix Gutiérrez, Francois Raffi, Ole Kirk, Murielle Mary-Krause, Christoph Stephan, Patricia Garcia de Olalla, Jodie Guest, Hasina Samji, Antonella Castagna, Antonella d'Arminio Monforte, Adriane Skaletz-Rorowski, Jose Ramos, Giuseppe Lapadula, Cristina Mussini, Lluís Force, Laurence Meyer, Fiona Lampe, Faroudy Boufassa, Heiner C Bucher, Stéphane De Wit, Greer A Burkholder, Ramon Teira, Amy C Justice, Tim R Sterling, Heidi M Crane, Jan Gerstoft, Jesper Grarup, Margaret May, Geneviève Chêne, Suzanne M Ingle, Jonathan Sterne, Niels Obel.   

Abstract

BACKGROUND: Some human immunodeficiency virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for failure to achieve CD4 count >200 cells/µL after 3 years of sustained viral suppression and (2) the association of the achieved CD4 count with subsequent mortality.
METHODS: We included treated HIV-infected adults from 2 large international HIV cohorts, who had viral suppression (≤500 HIV type 1 RNA copies/mL) for >3 years with CD4 count ≤200 cells/µL at start of the suppressed period. Logistic regression was used to identify risk factors for incomplete CD4 recovery (≤200 cells/µL) and Cox regression to identify associations with mortality.
RESULTS: Of 5550 eligible individuals, 835 (15%) did not reach a CD4 count >200 cells/µL after 3 years of suppression. Increasing age, lower initial CD4 count, male heterosexual and injection drug use transmission, cART initiation after 1998, and longer time from initiation of cART to start of the virally suppressed period were risk factors for not achieving a CD4 count >200 cells/µL. Individuals with CD4 ≤200 cells/µL after 3 years of viral suppression had substantially increased mortality (adjusted hazard ratio, 2.60; 95% confidence interval, 1.86-3.61) compared with those who achieved CD4 count >200 cells/µL. The increased mortality was seen across different patient groups and for all causes of death.
CONCLUSIONS: Virally suppressed HIV-positive individuals on cART who do not achieve a CD4 count >200 cells/µL have substantially increased long-term mortality.

Entities:  

Keywords:  CD4 cell recovery; HIV; mortality; risk factors; sustained viral suppression

Mesh:

Substances:

Year:  2014        PMID: 24457342      PMCID: PMC6276895          DOI: 10.1093/cid/ciu038

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.

Authors:  T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

2.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.

Authors: 
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.

Authors: 
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

Review 4.  The role of naïve T-cells in HIV-1 pathogenesis: an emerging key player.

Authors:  Gabriela Khoury; Reena Rajasuriar; Paul U Cameron; Sharon R Lewin
Journal:  Clin Immunol       Date:  2011-09-17       Impact factor: 3.969

5.  Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.

Authors:  Joanne Reekie; Csaba Kosa; Frederik Engsig; Antonella d'Arminio Monforte; Alicja Wiercinska-Drapalo; Pere Domingo; Francisco Antunes; Nathan Clumeck; Ole Kirk; Jens D Lundgren; Amanda Mocroft
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

6.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.

Authors:  Emilie Lanoy; Margaret May; Amanda Mocroft; Andrew Phillip; Amy Justice; Geneviève Chêne; Hansjakob Furrer; Timothy Sterling; Antonella D'Arminio Monforte; Lluís Force; John Gill; Ross Harris; Robert S Hogg; Jürgen Rockstroh; Mike Saag; Pavel Khaykin; Frank de Wolf; Jonathan A C Sterne; Dominique Costagliola
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

8.  CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Authors:  Nina Khanna; Milos Opravil; Hansjakob Furrer; Matthias Cavassini; Pietro Vernazza; Enos Bernasconi; Rainer Weber; Bernard Hirschel; Manuel Battegay; Gilbert R Kaufmann
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

9.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

10.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069

View more
  63 in total

1.  Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.

Authors:  Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy
Journal:  Int J STD AIDS       Date:  2017-03-21       Impact factor: 1.359

2.  Direct Targeting of Macrophages With Methylglyoxal-Bis-Guanylhydrazone Decreases SIV-Associated Cardiovascular Inflammation and Pathology.

Authors:  Joshua A Walker; Andrew D Miller; Tricia H Burdo; Michael S McGrath; Kenneth C Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

3.  A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the Caribbean.

Authors:  Mark J Giganti; Paula M Luz; Yanink Caro-Vega; Carina Cesar; Denis Padgett; Serena Koenig; Juan Echevarria; Catherine C McGowan; Bryan E Shepherd
Journal:  AIDS Res Hum Retroviruses       Date:  2015-03-06       Impact factor: 2.205

4.  Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.

Authors:  Rodolphe Thiébaut; Ana Jarne; Jean-Pierre Routy; Irini Sereti; Margaret Fischl; Prudence Ive; Roberto F Speck; Gianpiero D'Offizi; Salvatore Casari; Daniel Commenges; Sharne Foulkes; Ven Natarajan; Thérèse Croughs; Jean-François Delfraissy; Guiseppe Tambussi; Yves Levy; Michael M Lederman
Journal:  Clin Infect Dis       Date:  2016-02-07       Impact factor: 9.079

5.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

6.  Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Authors:  Paul Krogstad; Kunjal Patel; Brad Karalius; Rohan Hazra; Mark J Abzug; James Oleske; George R Seage; Paige L Williams; William Borkowsky; Andrew Wiznia; Jorge Pinto; Russell B Van Dyke
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

7.  HIV and Stem Cell Transplantation.

Authors:  Ignacio A Echenique; George E Nelson; Valentina Stosor; Christine M Durand
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

8.  Is CD4 monitoring needed among ugandan clients achieving a virologic and immunologic response to treatment?

Authors:  Steven J Reynolds; Joseph B Sempa; Agnes N Kiragga; Kevin Newell; Gertrude Nakigozi; Ronald Galiwango; Ron Gray; Thomas C Quinn; David Serwadda; Larry Chang
Journal:  AIDS Patient Care STDS       Date:  2014-10-07       Impact factor: 5.078

9.  Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy.

Authors:  David M Asmuth; Irina V Pinchuk; Jian Wu; Gracie Vargas; Xiaoli Chen; Surinder Mann; Anthony Albanese; Zhong-Min Ma; Ramez Saroufeem; Gregory P Melcher; Paolo Troia-Cancio; Natalie J Torok; Christopher J Miller; Don W Powell
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

10.  Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals.

Authors:  Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.